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Background: Recent studies suggested that leptin as a mitogenic factor might play an important role in the process
of initiation and progression of human cancer. Therefore, it could be considered as a target for breast cancer therapy.
A previous study has showed that expression of leptin gene could be modulated by activation of estrogen receptors.
Curcumin is a diferuloylmethane that has been shown to interfere with multiple cell signaling pathways and extensive
research over the last 50 years has indicated this polyphenol can both prevent and treat cancer. Based on the fact that
targeting of leptin could be considered as a novel strategy for breast cancer therapy, the aim of this study is the
investigation of potentiality of curcumin for inhibition of leptin gene expression and secretion, and also, its link with
expression of estrogen receptors.
Methods: Cytotoxic effect of curcumin on T47D breast cancer cells was investigated by MTT assay test after
24 and 48 treatments. Thereafter, the cells treated with different concentrations of curcumin. The levels of
leptin, estrogen receptor α and estrogen receptor β genes expression was measured in the treated and
control cells by Reverse-transcription real-time PCR. Amount of secreted leptin in the culture medium was also
determined by ELISA in both treated and untreated cells. Finally data were statistically analyzed by one-way
ANOVA test.
Results: Analysis of MTT assay data showed that curcumin inhibits growth of T47D cells with dose dependent
manner. There were also significant difference between control and treated cells in the levels of leptin, estrogen
receptor α expression levels and the quantity of secreted leptin that both were decreased in the treated cells
compared with control cells.
Conclusion: Based on the results, curcumin inhibits the expression and secretion of leptin and it could
probably be used as a drug candidate for the breast cancer therapy through the leptin targeting in the
future.
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Breast cancer is one of most commonly diagnosed types
of cancer among women in 2012 and expected to ac-
count for 29% (226,870) of all new cancer cases among
women [1]. Many factors are involved in the breast car-
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unless otherwise stated.Leptin, a 167 amino acids hormone with a molecular mass
of 16 kDa, is mainly secreted from adipose tissue [3]. It
has central roles in the control of satiety, energy expend-
iture, food intake, many reproductive processes [4], affect-
ing the metabolic and hematopoietic systems [5]. Beside
the synthesis by adipose tissue as the main source [6],
there have been identified other sources of leptin in the
body including testicles [7], ovaries [6], placenta [8], cartil-
age and bone cells [9], skeletal muscle [10] and stomach
[11]. Furthermore, the mitogenic, transforming or
migration-induced properties of leptin have been revealedentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[12], normal and neoplastic colon cells [13,14]; and also
normal and malignant mammary epithelial cells
[15,16]. It has been shown that leptin induces growth
and transformation in T47D breast cancer cells unlike
normal breast epithelial cells [17]. Leptin acts through
binding to its receptor known leptin receptor (ObR)
located in the target cell membrane [18]. Significantly
higher levels of both leptin and ObR expression have
been found in cancer tissue relative to non-cancer
epithelium [19]. Also, numerous breast cancer cell
lines such as MCF-7 and T47D could express leptin
and ObR [16]. All these observations confirm that
leptin can act not only by endocrine and (or) para-
crine action on mammary tumor cells, but also via an
autocrine pathway. Additionally, a significant positive
correlation has been obtained between leptin and ObR
expressions with breast cancer tissue [20]. Therefore,
this paracrine-autocrine leptin axis could become a tar-
get for leptin-inhibiting drugs in cancer treatment and
prevention.
Results of a study showed that the ratio of ERα to
ERβ, in human adipose tissue, was significantly corre-
lated with the level of serum leptin in vivo [21]. Thus,
ERα and ERβ maybe have different roles in the regula-
tion of leptin expression.
Curcumin (diferuloylmethane), a derivative of turmeric
is one of the most commonly used and highly researched
phytochemicals. It exhibits promising pharmacological
activities and has demonstrated beneficial effects in
terms of cancer cell proliferation, growth, survival, apop-
tosis, migration, invasion, angiogenesis, and metastasis
[22]. Considering important roles of leptin in the breast
cancer biology, in this study we investigated the possible
variations in the leptin secretion and expression as well
as expression of ERs in the T47D breast cancer cell line
after its treatment with pure curcumin.
Methods
Our study has been conducted on cell lines and it is
compatible with Helsinki ethical codes, and it has been
approved by ethics committee of our institute.
Chemicals and reagents
Curcumin (Sigma, Germany), MTT (Sigma, Germany),
Leptin ELISA kit (Labor diagnostika nord gmbh & co. kg,
Germany), Fetal bovine serum (Gibco, USA), Phenol-red
free RPMI 1640 with L-glutamine (Gibco, USA), T47D
cells (Pasteur Institute of Iran), Sodium bicarbonate
(Merck, Germany), Penicillin (SERVA, Germany), Strepto-
mycin (Merck, Germany), Amphotericin B (Merck,
Germany), TRIZOL Reagent (Invitrogen, USA), First-
Strand Synthesis kit (Fermentas, USA), Syber Green-I
reagent (Fermentas, USA).Cell culture
T47D cells were cultured in RPMI1640 (with glutamine)
supplemented with 10% FBS, penicillin, streptomycin
and amphotericin B and incubated at 37°C in a humidi-
fied atmosphere containing 5% Co2.
MTT assay and cell treatment
The cytotoxic effect of curcumin on T47D cells was
studied by 24 and 48 MTT assays. Briefly, 2500 cell/well
were cultivated in a 96 well culture plate. After 24 h in-
cubation in 37°C cells were treated with different con-
centrations of curcumin (0 to 100 μM) for 24 and 48 h
in the quadruplicate manner. Then, medium of all wells
were removed carefully and 50 μl 2 mg/ml MTT was
added to each well and incubated for 4.5 h, followed by
addition of 200 μl DMSO. Thereafter, Sorensens’ gly-
cine buffer was added and absorbance of each well was
read at 570 nm. For data analysis, mean OD of each
well was calculated. Then, percent of cells viability was
calculated according to this formula: percent of cells
viability = mean OD of test wells/mean OD of control
wells × 100. Finally, a graph was plotted using SPSS
16.0 and IC50 of curcumin on T47D was determined
on graph [23].
For studying the inhibitory effect of curcumin on
leptin, ERα and ERβ expression as well as leptin secre-
tion, 1×105 cells/wells were treated in a 6-well plate
with different concentrations of curcumin (0, 10, 20,
30 and 40 μM) for 24-48 h. A control group contain-
ing 0.1% DMSO without curcumin served as vehicle
control.
Isolation of total RNA and cDNA synthesis
Total RNA was extracted from attached cells using TRI-
ZOL Reagent according to the manufacturer’s instruc-
tions. The concentration of prepared RNA was measured
using a NanoDrop spectrophotometer (Termoscientific,
USA) and its integrity was confirmed by electrophoresis
on 1.5% agarose gel containing 1% formaldehyde. After
RNA preparation, cDNA was synthesized using the First-
Strand Synthesis kit according to the manufacturer’s in-
structions. The synthesized cDNA was immediately used
in a real-time PCR or stored at −70˚C for later use.
Real-time PCR
The real-time PCR was used for measurement of leptin,
ERα, and ERβ expression levels in the control and
treated cells. β-actin gene expression was used as the
internal control. The real-time PCR reaction was done
using the Syber Green-I reagent in the Rotor Gene
6000 system (Corbett research, Australia) according to
the manufacturer’s instructions in a triplicate manner.
The amplification conditions were as follows: leptin
(2 min at 95°C and a two-step cycle of 95°C for 15 s
Table 1 Primers used for real-time PCR amplifications
Primer Primer
length
Sequence (5′ to 3′) Product
size (bp)
Leptin forward 22 CACCAAAACCCTCATCAAGACA 80
Leptin reverse 24 CTTTCTGTTTGGAGGAGACTGACT
ERα forward 20 GCCAGCAGGTGCCCTACTAC 132
ERα reverse 23 TGGTACTGGCCAATCTTTCTCTG
ERβ forward 19 AAGAGCTGCCAGGCCTGCC 268
ERβ reverse 21 GCGCACTGGGGCGGCTGATCA
Β-actin forward 20 TGGACTTCGAGCAAGAGATG 137
Β-actin reverse 20 GAAGGAAGGCTGGAAGAGTG
Figure 1 The cytotoxic effect of curcumin on T47D cells during 24 h (
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and a two-step cycle of 95°C for 30 s and 57°C for 40 s
for 40 cycles), and ERβ (5 min at 95°C and a two-step
cycle of 95°C for 15 s and 64°C for 40 s for 40 cycles).
Sequences of used primers were shown in Table 1.
Changes in leptin, ERα, and ERβ expression levels be-
tween the control and treated T47D cells were calcu-
lated by the 2–ΔΔCT method.
Measurement of the secreted leptin
For analysis of possible effect of curcumin on amount
of secreted leptin in the treated cells compared with
the control cells, leptin concentration was measured in
the supernatant media of cells using a human leptin
ELISA kit according to the manufacturer’s instructions.A) and 48 h MTT assays.
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Statistical analysis was performed with SPSS 18.0 soft-
ware. Data are expressed as mean ± standard deviation.
All experiments were performed in triplicate. The dif-
ferences in expression levels of leptin, ERα and ERβ as
well as quantity of secreted leptin between the control
and treated cells were analyzed by one-way ANOVA,
followed by Dunett’s multiple comparison tests. A
p-value <0.05 was considered as significant.
Results
MTT assay
Data analysis of cytotoxicity assay showed that IC50 of
curcumin on T47D breast cancer cell line was 28 and
24 μM for 24 and 48 h MTT assays, respectively
(Figure 1). The obtained IC50s were dose-dependent.
Quantitative real- time PCR
Real-time PCR results showed a significant decrease in
leptin expression in the treated cells compared to the
control cells (p-value < 0.05) (Figure 2). We, also, mea-
sured the expression levels of ERα, and ERβ in the
treated and control cells. Although, no significant dif-
ference was detected in ERβ expression levels between
the treated and the control cells, a significant decrease
was observed in the ERα mRNA level (p-value < 0.05)
(Figure 3). Therefore, the ERα/ERβ expression ratio has
been decreased in the treated cells compared to the
control cells. There was no significant difference be-
tween the DMSO control and the DMSO-free control
(the 0 μM concentration of curcumin).
Data analysis revealed a positive significant link be-
tween leptin gene expression and ERα gene expression
level and no link between leptin and ERβ expression
level in curcumin treated cells compared to the controlFigure 2 Effect of curcumin on leptin expression levels in T47D cells.cells. In addition, a positive significant correlation was
found between mRNA level of leptin and ERα/ERβ ex-
pression ratio.
Measurement of secreted leptin
Amounts of secreted leptin were evaluated using ELISA.
A significant difference was found between the control
and treated cells in term of secreted leptin (Figure 4).
This finding was in accordance with inhibition of leptin
gene expression by curcumin.
Discussion
This study demonstrates that curcumin, most active
constituent of turmeric , can inhibit leptin gene expres-
sion and secretion in T47D breast cancer cells and this
decrease in leptin gene expression and secretion was
positively associated with decrease of ERα gene expres-
sion. These results indicate that curcumin has a strong
potential to interact with the expression of leptin gene,
which has significant roles in carcinogenesis and prolif-
eration of breast cancer cells [2]. Regarding to the crit-
ical role of leptin in breast carcinogenesis [24], there are
many attempts to inhibit leptin function and secretion.
Gonzalez et al. inhibited growth of murine mammary
cancer cell and xenograft tumor model of human breast
cancer cell lines by leptin peptide antagonist [25]. In
addition, leptin analog mimicking its action [26] and
anti-leptin receptor monoclonal antibody [27] are also
another approaches for interfering with the leptin func-
tion. In the other studies, administrations of some com-
pounds including b3-adrenoreceptor agonist, conjugated
linoleic Acid, isoflavone, resveratrol and bitter melon
lead to decreased secretion and lower levels of serum
leptin [28]. The current work, however, aimed to direct
inhibition of leptin expression and secretion in human
Figure 3 Effect of curcumin on expression levels of ERα (A) and ERβ (B) genes in the T47D cells. As the figure shows, there is a significant
decrease in ERα gene expression levels with increasing in the curcumin concentration (p-value < 0.05), unlike ERβ gene expression levels.
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nificant anti-cancer effects of curcumin on various types
of cancers such as gastrointestinal, genitourinary,
gynecological, hematological, pulmonary, thymic, brain,
breast, and bone [29], it can be used as a chemothera-
peutic agent for breast cancer therapy.
The mechanisms by which curcumin exerts its anti-
cancer effects are comprehensive and diverse, targeting
many levels of regulation in the processes of cellular
growth and apoptosis. Curcumin has an inhibitory effect
on both NF-κB and AP-1 activation. curcumin has been
shown to suppress the expression of a variety of NF-κB
regulated gene products involved in carcinogenesis
and tumor growth including cyclin D1, VEGF, COX-2,Figure 4 Effect of curcumin on leptin secretion in T47D cells.c-myc, Bcl-2, ICAM-1 and MMP-9 [30]. In addition,
Curcumin has been shown to suppress the expression of
cyclin D1 in many types of cancer including head and
neck, colon, bladder, breast, cervical and pancreatic car-
cinomas [31]. Our results, regarding inhibition of leptin
expression, confirm these findings, also demonstrating
another role for curcumin effect that probably acts
through estrogen receptors. It has been demonstrated
that expression of leptin has positive correlation with ex-
pression of ERα and negative correlation with ERβ ex-
pression [32]. In addition, leptin promoter has response
elements for both ERα and ERβ [33]; where, probably
competition between ERα and ERβ in attachment to this
place causes reduction of leptin gene transcription by
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and et al. reported that silibinin can decrease leptin gene
expression and secretion in T47D cells thought activa-
tion of ERβ gene expression [34]. In the current study,
we showed that reduction of leptin expression by curcu-
min positively correlates with expression of ERα. There-
fore, it seems that one of the possible mechanisms of
curcumin inhibitory effect on leptin expression could be
through ERs. However, many studies need to determine
the exact molecular mechanism (s) involved in the re-
duction of leptin gene expression and secretion by cur-
cumin [35-54].
Conclusion
In summary, we demonstrated that curcumin could in-
hibit expression and secretion of leptin in T47D breast
cancer cells. Regarding to the significant roles of leptin
in breast carcinogenesis, its inhibition could be consid-
ered as a novel strategy for treatment of breast cancer in
the future.
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